Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.

[1]  R. White,et al.  Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy , 2016, AIDS.

[2]  A. Zolopa,et al.  Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial , 2016, The Lancet.

[3]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[4]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[5]  R. Chaisson,et al.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  N. Shang,et al.  Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis , 2015, AIDS.

[7]  E. Gouws,et al.  Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[9]  Heather B. Blunt,et al.  Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews , 2014, BMC Infectious Diseases.

[10]  Kenneth H Mayer,et al.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. , 2014, The Lancet. Infectious diseases.

[11]  J. Kaewkungwal,et al.  Barriers to and Motivations for the Implementation of a Treatment Programme for Latent Tuberculosis Infection using Isoniazid for People Living with HIV, in Upper Northern Thailand , 2013, Global journal of health science.

[12]  S. Swaminathan,et al.  Efficacy of a Six-Month versus a 36-Month Regimen for Prevention of Tuberculosis in HIV-Infected Persons in India: A Randomized Clinical Trial , 2012, PloS one.

[13]  S. Lawn,et al.  Systematic Review of TST Responses in People Living with HIV in Under-Resourced Settings: Implications for Isoniazid Preventive Therapy , 2012, PloS one.

[14]  J. Montaner,et al.  Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts , 2011, Current HIV research.

[15]  R. Chaisson,et al.  New regimens to prevent tuberculosis in adults with HIV infection. , 2011, The New England journal of medicine.

[16]  K. Castro,et al.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[17]  S. Lawn,et al.  Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies , 2011, PLoS medicine.

[18]  R. Granich,et al.  Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions , 2010, AIDS.

[19]  S. Charalambous,et al.  Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study , 2010, AIDS.

[20]  S. Charalambous,et al.  Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme , 2010, AIDS.

[21]  R. Chaisson,et al.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort , 2009, AIDS.

[22]  L. Myer,et al.  Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  R. Chaisson,et al.  Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. , 2005, JAMA.

[24]  John L. Johnson,et al.  Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults , 2001, AIDS.

[25]  J. Pape,et al.  No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. , 2001, Journal of acquired immune deficiency syndromes.

[26]  D. Fuchs,et al.  Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults , 2001, AIDS.

[27]  J. Porter,et al.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia , 1998, AIDS.

[28]  R. Chaisson,et al.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection , 1998, The Lancet.

[29]  M. Vjecha,et al.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, The New England journal of medicine.

[30]  F. Plummer,et al.  Isoniazid preventive therapy for tuberculosis in HIV‐1‐infected adults: results of a randomized controlled trial , 1997, AIDS.

[31]  J. Pape,et al.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.

[32]  J. Volmink,et al.  Treatment of latent tuberculosis infection in HIV infected persons. , 2004, The Cochrane database of systematic reviews.

[33]  ohn,et al.  A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for Tuberculosis , 2000 .